2. Search Result
Search Result
Results for "

RRMM

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

5

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99730
    Mezagitamab
    1 Publications Verification

    TAK-079

    		 CD38 Apoptosis Inflammation/Immunology Cancer
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
    Mezagitamab
  • HY-P9989
    Linvoseltamab

    REGN5458

    		 CD3 TNF Receptor Cancer
    Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
    Linvoseltamab
  • HY-P9965
    Elotuzumab

    HuLuc 63; PDL 063; BMS 901608

    		 Transmembrane Glycoprotein Cancer
    Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
    Elotuzumab
  • HY-P99454
    Azintuxizumab vedotin

    ABBV-838

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
    Azintuxizumab vedotin
  • HY-171754
    LM-305

    		Antibody-Drug Conjugates (ADCs) Cancer
    LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
    LM-305
  • HY-P991490
    ISB2001

    		CD38 CD3 TNF Receptor Cancer
    ISB2001 is a human trispecific antibody (tsAb) targeting CD38 & CD3 & BCMA. BI-765423 can be used in relapsed/refractory multiple myeloma (RRMM) research. Recommended isotype control: IgG1-kappa-IgG1-Fab .
    ISB2001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: